GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Little Green Pharma Ltd (ASX:LGP) » Definitions » EBIT

Little Green Pharma (ASX:LGP) EBIT : A$-9.02 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Little Green Pharma EBIT?

Little Green Pharma's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2024 was A$-3.25 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was A$-9.02 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Little Green Pharma's annualized ROC % for the quarter that ended in Sep. 2024 was -8.38%. Little Green Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -9.17%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Little Green Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -23.82%.

Little Green Pharma EBIT Historical Data

The historical data trend for Little Green Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Little Green Pharma EBIT Chart

Little Green Pharma Annual Data
Trend Jun19 Jun20 Jun21 Mar23 Mar24
EBIT
- -8.99 24.70 -7.64 -7.55

Little Green Pharma Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Mar23 Sep23 Mar24 Sep24
EBIT Get a 7-Day Free Trial -8.21 - -1.78 -5.77 -3.25

Competitive Comparison of Little Green Pharma's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Little Green Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Little Green Pharma's EV-to-EBIT falls into.


Little Green Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-9.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma  (ASX:LGP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Little Green Pharma's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-6.428 * ( 1 - 0% )/( (78.486 + 74.917)/ 2 )
=-6.428/76.7015
=-8.38 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=86.29 - 2.83 - ( 4.974 - max(0, 6.425 - 21.474+4.974))
=78.486

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=83.048 - 3.299 - ( 4.832 - max(0, 7.935 - 20.941+4.832))
=74.917

Note: The Operating Income data used here is two times the semi-annual (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Little Green Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.492/( ( (60.995 + max(11.932, 0)) + (58.087 + max(10.615, 0)) )/ 2 )
=-6.492/( ( 72.927 + 68.702 )/ 2 )
=-6.492/70.8145
=-9.17 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.631 + 10.93 + 2.166) - (2.83 + 0 + 0.965)
=11.932

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.234 + 10.743 + 3.132) - (3.299 + 0 + 2.195)
=10.615

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Little Green Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-9.018/37.866
=-23.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma EBIT Related Terms

Thank you for viewing the detailed overview of Little Green Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Little Green Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Little Green Pharma Ltd (ASX:LGP) » Definitions » EBIT
Comparable Companies
ASX:CAN ASX:NXS ASX:ANP ASX:LV1 ASX:IVX ASX:EOF ASX:MVP ASX:ECS ASX:PXS ASX:IDT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
66 Kings Park Road, Level 2, Suite 2, West Perth, Perth, WA, AUS, 6005
Website
https://www.littlegreenpharma.com
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets.

Little Green Pharma Headlines

No Headlines